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Abstract 
 
Objective: This study aimed to assess a non-invasive haemoglobin sensor NBM 200 in 
pregnant women in a rural Indian setting. 
 
Methods: The study population consisted of women between 3 to 5 months of pregnancy, 
from 33 villages in Tuljapur and Lohara blocks of Osmanabad district, Maharashtra between 
April 2014 and June 2015. Haemoglobin (Hb) measurements obtained from the non-invasive 
sensor NBM 200 were compared with measurements obtained from an automated 
haematology analyser Sysmex XP-100, using the Bland Altman method and Spearman’s 
Rank correlation coefficient. Interclass correlation coefficient (ICC), sensitivity and specificity 
values were used to assess the anaemia diagnostic accuracy of NBM 200 against the gold 
standard (Sysmex XP-100).  
  
Results: Data were obtained from 269 pregnant women (median age: 21 years, Interquartile 
range: 19 to 23 years). Haemoglobin levels estimated by the Sysmex XP-100 analyser 
ranged from 5.5 g/dL to 14.1 g/dL (mean: 10.0 g/dL, standard deviation (SD): 1.28), while 
measurements obtained from NBM 200 ranged from 9.5 g/dL to 14.6 g/dL (mean: 11.9 g/dL, 
SD: 1.43). The Spearman’s test found a significant, moderately positive correlation between 
the two methods (rs= 0.4, p<0.001), ICC was 0.22, and the Bland-Altman analysis showed a 
mean difference of -1.8 g/dL (95% Confidence interval (CI): -2.06 to -1.71) indicating a 
systematic overestimation of Hb using the NBM 200. The NBM 200 showed low sensitivity 
(33.7%; 95% CI: 27.3 - 40.5) but high specificity (91.8%; 95% CI: 81.9 - 97.3) for the 
diagnosis of anaemia.  
 
Conclusion: Haemoglobin measurements obtained from the NBM 200 were higher with 
consequent underestimation of anaemia as compared with the gold standard reference 
method. This limits the use of the NBM 200 as an anaemia diagnostic test in our study 
population consisting of women during pregnancy.    
 
Keywords: Anaemia, Non-invasive Haemoglobin, NBM 200, Sysmex XP-100, Pregnancy, 
India.  
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Introduction 
 
Haemoglobin (Hb) is commonly used to measure anaemia status using an automated 
haematology analyser [1] but this requires both blood withdrawal and access to laboratory 
facilities. In developing countries, many individuals, often those with greater health needs, 
do not have easy access to diagnostic facilities [2]. Recently, the non-invasive haemoglobin 
sensor NBM 200 was introduced for Hb assessment, which provided an opportunity for 
anaemia screening at population level in developing countries [1, 2]. The NBM 200 sensor is 
a non-invasive portable device consisting of a finger probe and a processing unit with digital 
display. The finger-blood analyser uses occlusion spectrometry to estimate Hb in 
approximately 60 to 100 seconds [3].  
 
Recent studies conducted to validate NBM 200 mainly involved blood donation centers 
within hospital settings [4]. There is a strong clinical need to measure Hb levels accurately in 
settings where laboratory access is not easy, particularly during pregnancy where repeated 
measurements are required. However, there are no published evidences on the application 
of non-invasive Hb sensors outside hospital settings for antenatal anaemia screening [2, 4]. 
Thus it is an important area of research considering the high prevalence of anaemia in 
women during pregnancy in country like India [5, 6]. Moreover, there is little evidence for the 
accuracy of non-invasive haemoglobin sensors used in rural community settings. Therefore, 
the present study aimed to assess non-invasive haemoglobin measurements (using the 
NBM 200 sensor) against measurements obtained from a gold standard method using an 
automated haematology analyser (Sysmex XP-100) [7] among pregnant women living in 
rural India.   
 
Materials and Methods  
 
A cross-sectional study was conducted in 33 villages from Tuljapur and Lohara blocks, 
Osmanabad district, in the Indian state of Maharashtra with a catchment population of 
approximately 64,000 individuals. The primary aim of the study was to investigate the 
prevalence and risk factors of anaemia in pregnant women; this paper reports on a 
secondary aim which was to validate the use of the non-invasive Hb sensor NBM 200 as a 
screening test for anaemia in this population. The study population consisted of pregnant 
women between 3 to 5 months of pregnancy who provided data in the period 24th April 2014 
to 30th June 2015. Each participant was recruited after obtaining written consent in the 
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presence of a witness and the primary investigator (AA). Trained data assistants obtained 
the non-invasive haemoglobin measurements in accordance with manufacturer’s guidelines 
for the NBM 200 (Orsense Ltd, Nes-Ziona, Israel). Exclusion criteria were physical deformity 
of thumb of a non-dominant hand, any injury/ulcerations, localized infection, edema and skin 
breaks [8]. The gold standard measurement was obtained using a fully automated 
haematology analyser (Sysmex XP-100, Japan) on a venous blood sample at the 
haematology laboratory based in the Halo Medical Foundation’s (HMF) registered hospital at 
Andur, Maharashtra [7]. The non-invasive test was conducted in a sitting position in field 
(either at the participant’s home or in village health/nutrition center) followed by blood 
withdrawal within a 5-minutes interval [9]. For every participant, the non-dominant hand was 
used for venous blood withdrawal from the median cubital vein and the thumb of the same 
hand was used to obtain the non-invasive measurement [9]. The venous blood was obtained 
under an aseptic protocol using a 2-mL disposable sterile syringe. Each participant was 
asked to wait for 10 minutes after completion of both tests to ensure no adverse effect 
occurred post blood withdrawal. The blood sample was transferred to a 2-mL vacuum tube 
containing ethylenediaminetetraacetic acid (EDTA anticoagulant), which was then safely 
transported in a standard blood carrier container and tested in the HMF laboratory using 
Sysmex XP-100 within four hours of withdrawal. The analyser was calibrated everyday 
according to the manufacturer’s guidelines and standard laboratory protocol [7].   
 
Hb measurements obtained from each method were used to categorise each participant as 
having anaemia (Hb < 11 g/dL) or not [10].  We also classified participants as having severe 
anaemia if their Hb values were less than 7.0 g/dL [10]. Spearman’s rank correlation 
coefficient (rs) and Interclass correlation coefficient (ICC) was used to assess correlation and 
accuracy respectively, between the Hb measurements obtained from the two methods. 
Agreement between two methods was further investigated using the Bland-Altman analysis 
[11]. The diagnostic accuracy of the NBM 200 was then assessed against the Sysmex XP-
100 (the gold standard comparison in our study) [7]. The sensitivity (the proportion of true 
positives correctly identified by the NBM 200), specificity (the proportion of true negatives 
correctly predicted by the NBM 200), positive predictive value (PPV) i.e., the proportion of 
NBM 200 anaemia positive participants for whom the anaemia diagnosis was validated by 
the Sysmex XP-100, and negative predictive value (NPV) i.e., the proportion of NBM 200 
anaemia negative participants who were non anaemic as per the Sysmex XP-100 were 
estimated. All statistical analyses were conducted using Stata Statistical Software (v13.1, 
Texas, USA). The study was approved by the Institutional Ethics Committee of Government 
Medical College of Aurangabad, India (Reference number: Pharma/IEC/GMA/196/2014), 
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and also by the Nottingham University Medical School Research Ethics Committee 
(Reference number: E10102013).  
 
Results  
 
We approached 278 eligible pregnant women from 33 villages of Osmanabad district, of 
which 271 (97.5%) agreed to participate in the study. Due to a technical sensor error, the 
non-invasive haemoglobin readings of two participants could not be obtained, leaving 269 
samples (96.8% of the eligible women) for analysis. 
 
The median age of study participants was 21 years (Interquartile range: 19 to 23 years). The 
Hb estimated by Sysmex XP-100 (gold standard) ranged from 5.5 g/dL to 14.1 g/dL (mean: 
10.0 g/dL, Standard deviation (SD): 1.28), while the Hb estimated by the NBM 200 ranged 
from 9.5 g/dL to 14.6 g/dL (mean: 11.9 g/dL, SD: 1.43). The Sysmex XP-100 analyser (gold 
standard) results showed a high prevalence of anaemia (77.3%) in the study population with 
5 (1.9%) individuals classified with severe anaemia (Table 1).  The NBM 200 sensor 
measurements classified 27.9% of the study population with anaemia and none with severe 
anaemia.  
 
The Bland-Altman plot is presented in Figure 1. A comparison of measurements from the 
two Hb estimation methods yielded a mean difference of -1.8 g/dL (95% Confidence interval 
(CI): -2.06 to -1.71) suggesting a systematic overestimation of Hb using the NBM 200. In 
11.2% cases the NBM 200 yielded Hb measurements that were equal to or marginally 
higher than the measurements from the Sysmex XP-100. A statistically significant, 
moderately positive correlation was observed between NBM 200 and Sysmex XP-100 
measurements (Spearman’s correlation coefficient rs= 0.4, p<0.001).  Diagnostic accuracy 
for the NBM 200 for anaemia were as follows:  sensitivity 33.7% (95% CI: 27.3%, 40.5%), 
specificity 91.8% (95% CI: 81.9%, 97.3%), positive predictive value 93.3% (95% CI: 85.1%, 
97.8%), and negative predictive value 28.9% (95% CI: 22.6%, 35.8%). The ICC was 0.22 
(95% CI: -0.08 to 0.47) for an absolute agreement.  
 
Discussion 
 
In this study involving women during pregnancy, we found that haemoglobin measurements 
obtained from the NBM 200 were generally higher than the measurements obtained from the 
Sysmex XP-100 (gold standard). Consequently, the NBM 200 grossly underestimated the 
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anaemia prevalence in our study population (sensitivity of 33.7%). The ICC indicated fair 
agreement for NBM 200, however we identified possible patient safety concerns with the 
use of the NBM 200, considering all the severe anaemia cases in our study participants 
were misclassified as having moderate anaemia and would not have received appropriate 
clinical intervention had this method alone been used (Table 1).  
 
Our study has many strengths; to our knowledge it is the first where prospectively collected 
data are presented from a large representative population of pregnant women in a rural 
community setting [4]. The study population was drawn from marginalised and difficult to 
access areas where comparatively few healthcare facilities are available, and thus 
evaluating non-invasive portable technology in geographically remote areas is highly 
important. Secondly, our study recorded good response rate (96.8%), with only seven 
eligible women declining to participate. Lastly, the non-invasive readings were obtained in 
accordance with the manufacturer’s guidelines, and none of our subjects had thumb 
deformity, infection, ulcerations, edema, or skin colourants such as henna (locally known as 
Mehndi) [12]. However, a technical failure of the non-invasive sensor occurred twice during 
the study, which delayed data collection, and caused the loss of two samples as mentioned 
before.  
 
Our study findings are in agreement with those from a  study conducted at a blood center in 
Seoul, Korea by Kim et al. [13] where the NBM 200 Hb measurements tended to be higher 
than the LH500 automated hematology analyser estimates (Beckman Coulter Inc., Brea, 
CA, USA). The sensitivity (38.6%) and specificity (93.6%) analyses were very similar to our 
study and indicated that the NBM 200 failed to detect more than half of the ineligible blood 
donors. Though the correlation between these two techniques was satisfactory (rs 0.86), the 
strong agreement may not be the criteria for donor selection, as accurate blood parameters 
are prerequisites to prevent any ineligible donor selection. Similarly, an Italian study (n= 
3995 donors) showed a low sensitivity using NBM 200 (36.03% in men group and 45.76% 
among women) on comparison with the gold standard Beckman Coulter’s AcT-5 diff AL 
(Beckman Coulter Inc., Brea, CA, USA) [14]. However, our findings are in contrast to a 
recent study involving blood donors (n= 485, 94% men) from North India that reported a 
71.7% sensitivity for the NBM 200 when compared with the Sysmex KX-21 analyser 
(Sysmex Corporation, Kobe, Japan) (Table 2) [5]. Despite the high sensitivity, the Bland 
Altman limits of agreement were wide (Upper limit of agreement: 2.09 and Lower limit of 
agreement: -3.39) with poor correlation (rs= 0.43) between the two Hb estimation methods. 
About 45.5% of ineligible donors were not detected in the Indian study [5], similar to the 
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study by Kim et al [13]. A second study from Northwest India [6] involving 200 blood donors 
(96% men) showed high sensitivity (96.36%) when compared with the Sysmex KX-21 
analyser (Sysmex America Inc., Lincolnshire). The results by NBM 200 showed wide 
variation on assessing correlation with the gold standard; however the mean of difference 
was non-significant [6]. Belardinelli and colleagues [15] also reported high sensitivity (98%) 
and specificity (97%) in a similar study population. It is worth noting however, that all the 
patients in their study had Hb values above 13 g/dL (as ascertained using the Beckman 
Coulter AcT-5 diff cell counter) and unlikely to be representative of the general population. 
 
A study [8] involving pregnant women from Israel (n=63) reported Hb in the range 6.9 g/dL 
to 13.9 g/dL by the gold standard (LH750 analyser, Beckman Coulter Inc., Brea, CA, USA), 
which was lower than the range reported by the NBM 200 (7.7 g/dL to 14 g/dL). The Bland 
Altman analysis showed wide limits of agreement (-1.59 to 1.79) with a standard deviation 
error of 0.86 g/dL. The study concluded that the sensor measures haemoglobin accurately 
mainly based on a strong correlation, however, correlation measures association and not 
agreement [11, 13]. Secondly, the range of Hb values obtained by the gold standard and 
NBM 200 clearly indicate that the NBM 200 missed some severe anaemia cases similar to 
our experience [8]. Lastly, the study involved pregnant women from all trimesters 
(gestational age: average 35.9 weeks, range 13 to 41 weeks), where Hb is likely to vary [9], 
while our findings are based on larger sample size (n=269) between a fixed gestational 
period (3 to 5 months of pregnancy) and included a more detailed diagnostic analysis 
reporting the Bland Altman agreement method, sensitivity, specificity, NPV, PPV and 
correlation analyses.        
 
Previously published studies of the NBM 200 sensor (Table 2) have been mostly conducted 
in prospective blood donors [5, 6, 12, 14, 15], in whom Hb is likely to be higher than the 
general population. Moreover, the two Indian studies outlined earlier, had fewer than 7% 
women participants [5, 6]. A report from Indian National Family Health Survey 2005-06 
showed a 24% anaemia prevalence in men (aged 15-49 years), which was much lower than 
in women (55% prevalence, 15-49 years) [16]. Based on our results, the NBM 200 
underestimates anaemia prevalence; therefore, the validation of the non-invasive technology 
predominantly in male blood donors could explain the different findings.  The study by Singh 
et al. had a prevalence of 2.3% anaemic cases identified by the gold standard [5], and the 
study by Malukani et al. had only 17% anaemic cases [6] as compared to our study with 
77.3% anaemic cases, suggesting sampling variability [4]. Studies from Italy, Germany and 
France involved fairly equal number of men and women reporting to blood donation centers, 
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but anaemia prevalence is much lower in these countries compared to India. The German 
study reported a mean haemoglobin value of 13.4 g/dL (SD 0.93) in women (using gold 
standard, Sysmex KX-21) [12], while in our study settings in rural India mean haemoglobin 
was 10.0 g/dL (using gold standard, Sysmex XP-100). Similarly, the mean haemoglobin in 
the French study was 13.2 g/dL (95% CI: 11.9, 14.3) [1] and in the Italian study the boxplot 
indicated a mean Hb of 14.0 g/dL [15]. A systematic review and meta-analysis by Kim et al. 
[4] of non-invasive Hb sensor technologies (Radical 7, NBM 200, Pronto 7 and NBM 200MP) 
found that the pooled mean difference and SD were 0.10, + - 1.37 g/dL respectively (95% 
CI: -2.59, 2.80, I2 = 95.9% for mean difference and I2 =95.0% for SD). The review concluded 
that because of the wide limits of agreement with reference methods, clinical decisions 
based on non-invasive devices should be made cautiously. All studies included in the review 
were hospital-based, and none of the studies were from developing countries where 
anaemia prevalence is typically much higher.  
 
Conclusions and implications  
 
This is the first study conducted in a rural community setting where a representative sample 
of pregnant women was assessed. Our measurements were obtained in the field during a 
household survey which provided a unique opportunity to test the non-invasive technology in 
rural areas, where diagnostic facilities are limited. Globally, anaemia is a major public health 
issue affecting pregnant women particularly in developing country like India. Laboratory 
investigation of anaemia requires established infrastructure and the facility to transport blood 
samples. A portable non-invasive sensor that provides rapid results could provide 
opportunities for population level anaemia screening; however, the technology needs to be 
improved substantially to provide accurate readings in line with the accepted gold standard, 
before it can be implemented in a rural Indian population. As most studies, including our 
own, suggest a systematic overestimation of Hb values by the NBM 200, it may be possible 
for the manufacturer to improve the performance by recalibrating the sensor or algorithms 
that process the data collected. If the melanin content of subjects is demonstrated to 
interfere with Hb readings, then this would need further consideration. In future field-based 
research in developing countries following improvements to the sensor is required, before 
advocating the adoption of non-invasive technology for haemoglobin measurement and 
anaemia diagnosis.  
 
 
 
 9 
References 
 
1. Gayat E, Aulagnier J, Matthieu E, Boisson M, Fischler M. Non-invasive measurement 
of hemoglobin: assessment of two different point-of-care technologies. PLoS one 7: 
e30065 doi:10.1371/journal.pone.0030065 [published online first: 6 January 2012].  
2. PATH. Noninvasive anemia screening 2012. Available at: 
http://www.path.org/publications/files/TS_update_anemia.pdf (accessed 25 Aug 
2015).   
3. OrSense ltd. NBM 200. Available at: http://www.orsense.com (accessed 25 Aug 
2015).  
4. Kim SH, Lilot M, Murphy LS, Sidhu KS, Yu Z, Rinehart J, Cannesson M. Accuracy of 
continuous noninvasive hemoglobin monitoring: A systematic review and meta-
analysis. Anesth Analg 2014;119:332-46.  
5. Singh A, Dubey A, Sonker A and Chaudhary R. Evaluation of various methods of 
point-of-care testing of haemoglobin concentration in blood donors. Blood Transfus 
2015;13:233-39. 
6. Malukani P, Gajjar MD, Gonsai RN, Bhatnagar N, Goswami HM. Study of newer 
invasive and non-invasive methods of haemoglobin estimation in blood donor 
screening - a study on 200 donors. IJCRR 2014;6:26-30.  
7. Sysmex India Pvt Ltd. Available at: http://www.sysmex.co.in (accessed 25 Aug 2015). 
8. Hadar E, Raban O, Bouganim T, Tenenbaum-Gavish K, Hod M. Precision and 
accuracy of noninvasive hemoglobin measurements during pregnancy. J Matern Fetal 
Neonatal Med 2012;25:2503-06. 
9. Yoshida A, Saito K, Ishii K, Azuma I, Sasa H, Furuya K. Assessment of noninvasive, 
percutaneous hemoglobin measurement in pregnant and early postpartum women. 
Med Devices (Auckl) 2014;15:11-6. 
10. National Family Health Mission, Ministry of Health and Famly Welfare, Government of 
India. Available at: http://nrhm.gov.in/nrhm-components/rmnch-a/child-health-
immunization/child-health/guidelines.html (accessed 15 Aug 2015).  
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two 
methods of clinical measurement. Lancet 1986;1:307-10.  
12. Ardin S, Störmer M, Radojska S, Oustianskaia L, Hahn M, Gathof BS. Comparison of 
three noninvasive methods for hemoglobin screening of blood donors. Transfusion 
2015;55:379-87.  
13. Kim MJ, Park Q, Kim MH, Shin JW, Kim HO. Comparison of the accuracy of 
noninvasive hemoglobin sensor (NBM-200) and portable hemoglobinometer 
(HemoCue) with an automated hematology analyzer (LH500) in blood donor 
screening. Ann Lab Med 2013;33:261-67.  
14. Pagliaro P, Belardinelli A, Boko V, Salamon P, Manfroi S, Tazzari PL. A non-invasive 
strategy for haemoglobin screening of blood donors. Blood Transfus 2014;12:458-63.  
15. Belardinelli A, Benni M, Tazzari PL, Pagliaro P. Noninvasive methods for 
haemoglobin screening in prospective blood donors. Vox Sang 2013;105:116-20.  
16. Arnold F, Parasuraman S, Arokiasamy P, Kothari M. Nutrition in India in National 
Family Health Survey (NFHS-3) India 2005-06. Available at:  
http://www.rchiips.org/nfhs/nutrition_report_for_website_18sep09.pdf (accessed 30 
Aug 2015). 
 
 
 
 
 
 
 
 10 
Funding Source:The study was a part of postgraduate research programme of Dr. 
Anand Ahankari with the University of Nottingham, UK. The PhD study was sponsored by 
the Vice Chancellor Scholarship for Research Excellence 2013 granted by the University 
of Nottingham, UK (Ref 12031). The project was implemented in India as a joint 
collaboration with the Halo Medical Foundation, which was supported by Dr. Hardikar 
through the Maharashtra Foundation, USA. The non-invasive NBM 200 unit was 
sponsored by the Clinical Translational Research Priority Group Award for International 
Collaboration, University of Nottingham, UK (Grant Code: A2RN72). Professor (Mr) and 
Mrs Chawathe, Mumbai, India provided generous support for Dr Ahankari’s study. Dr 
Ahankari also received a bursary from Durgadevi Charitable Turst, India during PhD 
programme.  
 
Financial disclosure: Donors/Organisations/Individuals outlined above have had no role 
in defining the study hypothesis, data collection, data analysis, interpretation or 
manuscript preparation.  
 
Conflicts of interest: Authors have no conflicts of interest to disclose that are relevant to 
this study.  
 
Author contributions: The study was designed by AF, PM, LT and AA. AA obtained the 
data and AA, PM and AF conducted the analysis. All authors (PM, LT, JD, AA and AF) 
participated in manuscript preparation and approved the manuscript for publication.  
 
Acknowledgments: We acknowledge support of Ms. Sandhya Rankhamb in data 
collection, data entry, verification, and recognise her contribution in the project. We thank 
HMF village health workers for providing field level support for this study. We dedicate 
our research to Dr Sulbha Hardikar and Professor (Mr) and Mrs Chawathe who 
supported the project and PhD studies respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11 
Figure legends  
 
Figure 1 Bland-Altman Analysis of Sysmex XP-100 and NBM 200 Haemoglobin 
measurements 
 
Footnote for figure 1:  
* ULA: Upper limit of agreement, LLA: Lower limit of agreement  
LLA -4.79 g/dL and ULA 1.01 g/dL, Mean difference -1.8 g/dL (95% CI: -2.06 to -1.71).  
 
 
 
Table 1 Cases of severe anaemia which were measured as moderate anaemia by the 
non-invasive sensor  
 
No Hb measurement by  
Sysmex XP-100 
haematology analyser 
Hb measurement by NBM 
200 sensor for the same 
participant 
1 5.5 g/dL 9.5 g/dL 
2 6.1 g/dL 9.5 g/dL 
3 6.3 g/dL 9.5 g/dL 
4 6.8 g/dL 10.1 g/dL 
5 6.8 g/dL 9.5 g/dL 
 
Figure 1: Bland Altman Plot of NBM200 and Sysmex XP-100 
 
 
 
 
 12 
Table 2 Published studies conducted to validate NBM 200 sensor 
  
Ref First author, 
year of 
publication 
Study 
settings 
Country, 
population and 
sample size 
Method of 
comparison and 
gold standard used 
NBM 200 performance 
1 Gayat 
Etienne et al, 
2012 
Emergency 
department, 
Foch university 
hospital, 
Suresnes, 
France.  
France 
Patients 
reporting to 
emergency 
department  
 
n=569 and for  
NBM 200 n= 
297 (men 157 
and women 
140) 
 
Males 52.9% 
Females 47.1% 
 
Data analysed 
for 270 patients.  
Descriptive data, 
student t test, Bland 
Altman analysis, 
Intra-class 
correlation, 
Multivariate linear 
regression to identify 
variables associated 
with bias.  
 
 
ADVIA 2120 
(Siemens Medical 
Solutions 
Diagnostics, Zurich, 
Switzerland). 
Bias: 0.21 g/dL (95% CI: 0.02, 0.39) 
 
Bland Altman analysis  
Upper limit of agreement: 3.42 g/dL (95% CI: 3.10, 3.74) 
Lower limit of agreement: -3.01 g/dL (95% CI: -3.32, -2.69) 
 
Intra-class correlation coefficient: 0.69 (95% CI: 0.62, 0.75) 
Coefficient of variation (CV): 5.9% 
 
True values of haemoglobin and perfusion index were 
independently associated with NBM 200.  
 
Despite the limited bias, wide level of agreement was 
found, thus clinical usefulness is debatable.  
 
5 Singh Abhay 
et al, 2015 
Blood donation 
center in 
tertiary care 
institute, India.  
 
 
India 
Blood donors 
 
n= 534, and 485 
included in the 
analysis for 
NBM 200 (men 
455, women 30) 
 
n= 485  
Males 94% 
Females 6% 
 
Bland Altman 
analysis, intra-class 
correlation coefficient, 
Specificity, 
Sensitivity, Negative 
predictive value 
(NPV) and Positive 
predictive value 
(PPV).   
 
Sysmex KX-21 
(Sysmex Corporation, 
Kobe, Japan).  
 
Mean Hb by NBM 200:14.8 g/dL  
Mean Hb by the gold standard: 14.1 g/dL 
 
SD for NBM 200 > 2.0 g/dL, on comparing with gold 
standard.  
 
Bland Altman Agreement   
ULA: 2.09 g/dL (95% CI: 1.88, 2.30) 
LLA : - 3.39 g/dL (95% CI : - 3.61, - 3.19)  
 
Bias: -0.66 g/dL (95% CI: -0.78, -0.53) 
 
Sensitivity 71.7%, Specificity 79.5%, 
NPV 95.8%, PPV 30.2% 
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Intra-class correlation: 0.43 (95% CI: 0.27, 0.55) 
 
NBM 200 did not detect 45.5% of ineligible donors.  
 
NBM 200 has benefit of pain elimination but carries a 
substantial possibility of ineligible donor selection.  
6 Malukani 
Pankaj et al, 
2014 
Blood donation 
center in 
tertiary care 
hospital, 
Ahmedabad, 
Gujarat, India. 
India 
Blood donors 
 
n= 200 (men 
192, women 8) 
 
Males 96% 
Females 4% 
Specificity, 
Sensitivity, Negative 
predictive value and 
Positive predictive 
value.   
 
Sysmex KX 21 
(Sysmex America 
Inc., Lincolnshire).  
Mean Hb by NBM 200: 13.5 g/dL (SD 1.4) 
 
Sensitivity 96.36%, Specificity 91.43%,  
NPV 84.21%, PPV 98.15% 
Likelihood ratio 8.22 
 
The results by NBM 200 showed wide variation when 
compared with the gold standard, but the mean of 
difference was non-significant.  
8 Hadar Eran 
et al, 2012 
Women’s 
hospital, Rabin 
Medical 
center, Petah 
Tikva, Israel.   
Israel   
Pregnant 
women  
 
n= 63 
 
Average age 
31.3 years  
(range 21 to 25) 
 
Average 
gestational age 
35.9 weeks 
(range 13 to 41 
weeks) 
Bland Altman 
analysis  
 
LH750 automated 
hematology analyser 
(Beckman Coulter 
Inc., Brea, CA, USA). 
Hb Range obtained by NBM 200: 7.7 g/dL to 14.0 g/dL 
 
SD 0.86 g/dL 
 
Bland Altman Agreement: -1.59 g/dL to 1.79 g/dL 
 
Correlation coefficient: 0.82 
Mean absolute error: 0.71 g/dL 
 
Hb Range obtained by gold standard: 6.9 g/dL to 13.9 g/dL 
 
Study demonstrates good correlation with gold standard 
and NBM 200 measure Hb accurately.  
12 Sergey Ardin 
et al, 2015 
Blood donation 
center of the 
Institute for 
Transfusion 
Germany  
Blood donors 
 
Donors age 
Bland Altman 
analysis  
 
Sysmex KX-21n, 
SD for NBM 200 1.14 g/dL, on comparing with gold 
standard  
 
Bland Altman Agreement: -2.35 g/dL to 2.11 g/dL 
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Medicine of 
the University 
Hospital of 
Cologne, 
Germany. 
mean 36 years 
(SD 14) 
n= 351, and for  
 
NBM 200 
n= 120 (through 
phase 1 of the 
study, 78 men 
and 42 women). 
 
Men 65% 
Women 35% 
(Sysmex Europe 
GmbH, Norderstedt, 
Germany).  
 
Bias: -0.12 g/dL 
 
False rejection of seven donors, however no 
correspondent unacceptable classification occurred.  
 
NBM 200 obtained lower haemoglobin levels in women.  
 
 
13 Kim Moon 
Jung et al, 
2013 
Two blood 
donation sites 
affiliated to the 
Hanmaum 
Blood center, 
Gwacheon, 
Korea. 
Korea 
Blood donors 
 
n= 506 (men 
291, women 
215) 
 
Males 57.5% 
Females 42.4% 
Bland Altman 
analysis, Specificity 
and Sensitivity.  
 
LH500 automated 
hematology analyser 
(Beckman Coulter 
Inc., Brea, CA, USA). 
Mean Hb by NBM 200: 14.1 g/dL 
 
Intra-class correlation between NBM 200 and LH500: 0.86 
 
NBM 200 
Hb < 12.0 g/dL in 37 participants (mean 12.4, SD 1.2) 
Hb = 12.0 to 12.4 g/dL in 18 participants (mean 12.8, SD 
1.1)  
Hb ≥ 12.5 g/dL in 451 participants (mean 14.4, SD 1.2)  
 
Bland Altman plot showed 2 SD difference in haemoglobin 
estimations between LH500 and NBM 200, Hb > 2.0 g/dL.  
 
Whole blood 
Sensitivity 38.6% (95% CI: 28.1, 50.3) 
Specificity 93.6% (95% CI: 90.9, 95.5) 
 
Apheresis 
Sensitivity 37.8% (95% CI: 24.1, 53.9) 
Specificity 94.0% (95% CI: 91.5, 95.8) 
  
Out of 70 ineligible donors (Hb < 12.5 g/dL) according to 
the gold standard (LH500), 43 donors (61.45%) were 
considered eligible by the NBM 200.    
 15 
14 Paglirao 
Pasqualepao
lo et al, 2014 
Immunohemat
ology and 
Transfusion 
Medicine 
Collection site 
of S. Orsola 
Malpighi 
Hospital, 
Bologna, Italy. 
Italy  
Blood donors 
 
Data from year 
2012  
NBM 200 (n) 
Men= 2945 
Women=1021  
 
Data from year 
2013 (n) 
NBM 200 
Men= 2895  
Women=1100 
Specificity, 
Sensitivity, Negative 
predictive value and 
Positive predictive 
value.   
 
Donors were 
classified into fit and 
unfit sections.  
 
Hematocytometry 
tests as a reference 
in year 2012.  
 
Beckman Coulter’s 
AcT-5 diff AL 
(Beckman Coulter 
Inc., Brea, CA, USA) 
as a gold standard in 
year 2013.   
 
2012: NBM 200 and Hematocytometry test 
 
Women (n= 1021) 
Sensitivity 32.34%, Specificity 95.12%, 
NPV 85.15% and PPV 61.90% 
 
Men (n= 2945) 
Specificity 98.89%, Sensitivity 14.47% 
NPV 95.30% and PPV 42.59% 
 
2013: NBM 200 + targeted venous sample (gold standard, 
Beckman Coulter)  
 
Women (n= 1100) 
Sensitivity 45.76%, Specificity 99.24%, 
NPV 90.51% and PPV 92.05% 
 
Men (n= 2895) 
Sensitivity 36.03%, Specificity 99.93%,  
NPV 96.94% and PPV 96.08% 
 
Compared to non-invasive techniques, a venous sample 
improves donor selection.  
15 Belardinelli A 
et al, 2013 
Immunohemat
ology and 
Transfusion 
Medicine 
Collection site 
of S. Orsola 
Malpighi 
Hospital, 
Bologna, Italy. 
Italy 
Blood donors 
 
n= 445 (men 
296, women 
149) 
 
Males 66.5% 
Females 33.4% 
Bland Altman 
analysis, Specificity 
and Sensitivity.  
 
Beckman Coulter’s 
AcT-5 diff AL 
(Beckman Coulter 
Inc., Brea, CA, USA).  
 
Bland Altman Agreement: -1.64 g/dL to 2.21 g/dL 
Bias: 0.29 g/dL 
SD: 0.98 g/dL  
 
Percentage of donors screened correctly by NBM 200: 
88% 
 
Sensitivity 98%, Specificity 97%  
 
Non-invasive technique does not replicate results of 
venous sample, and compared to finger-prick (HamoCue), 
the NBM 200 had low sensitivity and specificity.  
 
